<DOC>
	<DOCNO>NCT01231841</DOCNO>
	<brief_summary>RATIONALE : Immunosuppressive therapy , anti-thymocyte globulin cyclosporine , may improve bone marrow function increase blood cell count . PURPOSE : This phase II trial study well give anti-thymocyte globulin together cyclosporine first-line therapy work treat patient severe aplastic anemia .</brief_summary>
	<brief_title>Anti-thymocyte Globulin Cyclosporine First-Line Therapy Treating Patients With Severe Aplastic Anemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : To determine response rate r-ATG CsA first line set . SECONDARY OBJECTIVES : To determine level IS assess Immuknow assay responder compare non-responders . OUTLINE : Patients receive anti-thymocyte globulin IV 4-24 hour daily day 1-5 . Beginning day 6 , patient receive oral cyclosporine twice daily 6 month follow taper . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>All patient sAA define Camitta candidate IS therapy ; criterion include bone marrow cellularity &lt; 25 % 2550 % &lt; 30 % hematopoietic cell ; also two follow three parameter : peripheral blood neutrophil &lt; 0.5 x 10^9/L , platelet &lt; 20 x 10^9/L reticulocyte &lt; 60 x 10^9/L anemic patient If cytogenetic test do , show normal karyotype informative Patients either unwilling otherwise ineligible ( age , comorbidities , lack donor ) bone marrow transplantation therapeutic modality Not previously treat ATG sAA Patients must ECOG performance status 0 , 1 , 2 Vitamin B12 folic acid deficiency must rule measurement serum level Patients must bone marrow biopsy examination three month prior enrol study Must able provide inform consent Systemic hematologic cause pancytopenia , base clinical presentation , must rule Patients clinically evident congestive heart failure , serious cardiac arrhythmia ; symptom coronary artery disease must clear cardiology prior therapy Patients chemotherapy , radiotherapy , immunotherapy investigational drug use within 3 week prior study entry Pregnant woman All female childbearing potential must blood test urine study within two week prior induction registration rule pregnancy Women childbearing potential strongly advise use accept effective method contraception Patients medical , psychological , social condition may interfere patient 's participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>